EMA confirms Mangoral eligible for the centralized regulatory procedure in the EU

2020-11-03
Download
Ascelia Pharma AB (publ) (ticker: ACE) today announced that it has received confirmation from the European Medicines Agency (EMA) that a Marketing Authorization Application (MAA) for Mangoral is eligible to be submitted in the European Union (EU) under the Agency’s centralized procedure. Mangoral is Ascelia Pharma’s lead drug candidate, currently in Phase 3 development.

The centralized procedure permits the submission of a single marketing application to the EMA that, if approved, allows the drug to be marketed in all EU member states, rather than requiring independent national procedures. The centralized process (Article 3(2)b) is granted to drug candidates that the agency considers as a therapeutic, scientific or technical innovation.

“We are pleased that the EMA regards Mangoral as being eligible for a centralized regulatory review, in accordance with our expectations. We appreciate that Mangoral, as a novel liver contrast agent to patients, is being classified in the therapeutic innovation category. Today’s decision from the EMA marks yet another step in our market launch preparations”, said CEO Magnus Corfitzen.

For further information, please contact:
Magnus Corfitzen, CEO

Email: moc@ascelia.com
Tel: +46 735 179 118

Mikael Widell, Head of IR & Communications
Email:
mw@ascelia.com

Tel: +46 703 11 99 60
 

The information was submitted for publication, through the agency of the contact persons set out above, at 3.30pm CET on November 3, 2020.

About Ascelia Pharma

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Mangoral and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com.

About Mangoral

Mangoral (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Mangoral, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is currently in Phase 3 development, including the global multi-center SPARKLE study.

2021-04-09

Issue and repurchase of series C shares for share saving program

Pursuant to the authorization granted by the annual general meeting on 6 May 2020, the board of directors of Ascelia Pharma AB (”Ascelia Pharma”) has resolved to issue and immediately thereafter repurchase 397,641 series C shares. The shares are issued and repurchased in accordance with the share saving program LTI 2020, which was adopted by the annual general meeting on 6 May 2020.
2021-03-31

NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB

The shareholders in Ascelia Pharma AB, Reg. No. 556571-8797 (“Ascelia Pharma”), are hereby invited to the annual general meeting (Sw. årsstämma) to be held on Wednesday 5 May 2021.
2021-03-31

Number of shares and votes in Ascelia Pharma AB

During March 2021, the number of shares and votes in Ascelia Pharma AB have increased by 481,573 due to the exercise of in total 481,573 warrants under the company’s incentive program.